By combining structural insights with our antibody drug discovery platform and deep understanding of the underlying biology, our scientific outlook is all-encompassing. We consider ideas, findings, and beliefs about validated targets (past and present) and extend them with our critical science to realize great pharmacological potential.
Structural Insights & the Growth Factor Precursor
Unlike traditional approaches, we target growth factors in their inactive precursor, or latent, forms to selectively regulate their activity in the microenvironment of cells and tissues. We applied this extraordinary selectivity across a number of growth factors, including to transforming growth factor beta (TGFβ), and are on the path to achieving novel discoveries.
Our proprietary platform aids in our development of antibody drugs that apply to targets living in the scientific crossroads of biologically understood and structurally misunderstood.
Recent PublicationsView More Publications
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
April 17, 2020
Journal of Biological Chemistry
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
Recent PostersView More Posters
2021 Virtual American Academy of Neurology (AAN) Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): Interim Analysis Results
American Association for Cancer Research (AACR) Annual Meeting 2021
Development of a Comprehensive Biomarker Strategy to Support the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON
2021 MDA Virtual Clinical & Scientific Conference
Apitegromab, a Novel High-Affinity Anti-proMyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis (Presentation)